Table 2. Major adverse events in each groups.
| Major events | AVR | MVR | DVR |
|---|---|---|---|
| Total follow-up (months) | 147.3 ± 53.2 | 151.9 ± 54.5 | 159.8 ± 49.2 |
| (3362.7 pat-year) | (9420.5 pat-year) | (4779.6 pat-year) | |
| Late death | 27 (9.9%) | 36 (4.8%) | 14 (3.9%) |
| Thromboembolism | 13 (4.7%) | 24 (3.2%) | 13 (3.6%) |
| Valve thrombosis | 04 (1.5%) | 38 (5.1%) | 13 (3.6%) |
| Fibrinolysis = 3 | Fibrinolysis = 26 | Fibrinolysis = 9 | |
| Endocarditis | 7 (2.6%) | 2 (0.2%) | 03 (0.9%) |
| Para-valvular leak | 02 | 01 | 03 (0.9%) |
| Pannus formation | 06 (2.2%) | 0 | 23 (6.4%) |
| Bleeding | |||
| Mild or moderate | 31 (11.3%) | 104 (14%) | 57 (15.9%) |
| Severe | 7 (2.6%) | 29 (4%) | 11 (3.1%) |
| Reoperation | 10 (3.6%) | 26 (3.5%) | 23 (6.4%) |
AVR: aortic valve replacement; DVR: double valve replacement; MVR: mitral valve replacement